H N Sather - Concepedia

Author

H N Sather

Children's Oncology Group

Also Known As

H N Sather, H Sather, H. N. Sather, H. Sather, HARLAND N. SATHER, HarlandN Sather, HarlandN. Sather

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Children's Oncology Group Children's National University of Southern California Parker Hughes Cancer Center University of Chicago

About

H N Sather is an author at Children's Oncology Group specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	923
2	Health Sciences	8	8	592
3	Public Health	1	1	144
4	Gastroenterology	1	1	12
5	Hepatology	1	1	12

H N Sather

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
PRESYMPTOMATIC CENTRAL NERVOUS SYSTEM THERAPY IN PREVIOUSLY UNTREATED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA: COMPARISON OF 1800 RAD AND 2400 RAD M E Nesbit, L. L. Robison, P S Littman, The Lancet Hematological MalignancyNeuro-oncologyLymphoid NeoplasiaPediatric HematologyMixed-phenotype Acute Leukemia	1981	163
Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. Fatih M. Uckun, Martha G. Sensel, H N Sather, Journal of Clinical Oncology	1998	145
Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. Charles A. Sklar, L. L. Robison, M E Nesbit, Journal of Clinical Oncology SpermatogenesisRadiation EffectReproductive HealthRadiation ExposureGynecology	1990	144
Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. James B. Nachman, H N Sather, Joel M. Cherlow, Journal of Clinical Oncology	1998	133
Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. James B. Nachman, H N Sather, P S Gaynon, Journal of Clinical Oncology	1997	121
Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. W. Archie Bleyer, Peter F. Coccia, H N Sather, Journal of Clinical Oncology PharmacotherapyMetronomic ChemotherapyHematological MalignancyNeuro-oncologyCns Leukemia	1983	120
INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND UNFAVOURABLE PRESENTING FEATURES PaulS. Gaynon, W. Archie Bleyer, VincentC. Albo, The Lancet Hematological MalignancyLymphoid NeoplasiaPediatric HematologyMixed-phenotype Acute LeukemiaMalignant Blood Disorder	1988	117
Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. Nyla A. Heerema, H N Sather, Martha G. Sensel, Journal of Clinical Oncology	1998	113
Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. Fatih M. Uckun, P S Gaynon, Martha G. Sensel, Journal of Clinical Oncology	1997	106
Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: A Report from Children's Cancer Study Group. M E Nesbit, H N Sather, L. L. Robison, PubMed Bone Marrow RemissionHematological MalignancyNeuro-oncologyRadiation MedicineHematology	1982	83

Page 1